Asthma Medication Classification

A patient grabs their inhaler during an acute attack — but it's their controller, not their rescue. Knowing which drug does what determines whether you save the airway or watch it close.

Asthma medications split into two functional categories: quick-relief (rescue) and long-term control (maintenance). Rescue medications are short-acting beta-2 agonists (SABAs) like albuterol, which relax bronchial smooth muscle within minutes and last 4–6 hours. They treat acute bronchospasm only — they do not reduce inflammation. Long-term controllers prevent attacks. Inhaled corticosteroids (ICS) such as fluticasone and budesonide are the cornerstone — they suppress airway inflammation and are taken daily regardless of symptoms. Long-acting beta-2 agonists (LABAs) like salmeterol are add-on therapy to ICS, never used as monotherapy because they don't address inflammation and carry a black box warning for increased asthma-related death when used alone. Leukotriene receptor antagonists (montelukast) block inflammatory mediators and serve as adjuncts. Mast cell stabilizers (cromolyn) are preventive only, used before allergen exposure. The administration sequence matters: when a patient uses both a bronchodilator and a corticosteroid inhaler, the bronchodilator is traditionally given first — it opens airways so the steroid penetrates deeper.

Key Distinctions

Don't confuse SABAs (albuterol — rescue, rapid onset) with LABAs (salmeterol — maintenance, slow onset, never for acute attacks). Students mix up ICS with oral corticosteroids: ICS are daily controllers with local side effects (oral thrush, hoarseness); oral steroids are reserved for acute exacerbations and carry systemic risks. Montelukast is a controller pill, not a rescue medication — it won't stop an active attack.

Clinical Pearl

Rescue then controller: bronchodilator opens the door, corticosteroid walks in. And always rinse the mouth after inhaled steroids — thrush is the giveaway you forgot.